Yeini, Eilam http://orcid.org/0000-0003-3491-3994
Ofek, Paula
Pozzi, Sabina http://orcid.org/0000-0002-6299-9273
Albeck, Nitzan http://orcid.org/0000-0002-2121-4046
Ben-Shushan, Dikla http://orcid.org/0000-0002-7576-0149
Tiram, Galia http://orcid.org/0000-0002-5425-8088
Golan, Sapir http://orcid.org/0000-0002-7610-2746
Kleiner, Ron http://orcid.org/0000-0002-4638-4738
Sheinin, Ron
Israeli Dangoor, Sahar http://orcid.org/0000-0001-8768-4350
Reich-Zeliger, Shlomit
Grossman, Rachel
Ram, Zvi
Brem, Henry http://orcid.org/0000-0001-7539-4786
Hyde, Thomas M. http://orcid.org/0000-0002-8746-3037
Magod, Prerna
Friedmann-Morvinski, Dinorah http://orcid.org/0000-0002-6394-9876
Madi, Asaf http://orcid.org/0000-0003-3441-3228
Satchi-Fainaro, Ronit http://orcid.org/0000-0002-7360-7837
Article History
Received: 11 August 2020
Accepted: 1 March 2021
First Online: 26 March 2021
Competing interests
: H.B. is a consultant for AsclepiX Therapeutics, Perosphere Inc., StemGen, InSightec, Accelerating Combination Therapies, Camden Partners, LikeMinds, Inc., Galen Robotics, Inc., Nurami Medical and Be Cured: Fighting Brain Cancer. R.S.F. is a Board Director at Teva Pharmaceutical Industries Ltd. All other authors have no competing interests to declare.